For its first fiscal quarter (ending March 31), Theravance Biopharma Inc (NASDAQ: TBPH) has reported E.P.S. of $-0.24 compared to $-0.35 a year ago. For the latest four quarters through March 31, E.P.S. were $-0.86 compared to $-1.07 a year ago.
Recent Price Action
Theravance Biopharma Inc (NASDAQ: TBPH) stock enjoyed a large increase of 2.1% on 5/13/24. The stock closed at $9.58. However, trading volume in this advance was exceptionally low at 45% of normal. The stock has been weak relative to the market over the last nine months but has risen 1.3% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, TBPH is expected to be a Value Builder.
Theravance Biopharma has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing complementary signals. Theravance Biopharma has a slightly negative Power Rating of 31 and a very low Appreciation Score of 13, with the Lowest Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment